Pancreatic Cancer Research

ResearcherUniversity of LiverpoolActive in the last 2 years

Bengt L. G. Glimelius

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5440-791X; OpenAlex author ID A5053292011, A5057158252, A5107392478. Sources: OpenAlex.

Their work

Papers
15
Trials
0
Grants
0
Labs led
0
Collaborators
94
Papers, trials and grants by year

2014: 3 papers · 2015: none · 2016: 3 papers · 2017: 1 paper · 2018: 3 papers · 2019: 3 papers · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 15

  1. Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. Co-author DOI 10.1200/jco.24.01118↗
  2. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Co-author DOI 10.3390/cancers13225758↗
  3. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. Co-author DOI 10.1001/jamasurg.2019.3337↗
  4. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002557↗
  5. Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre pha… Co-author DOI 10.1177/1758835918818351↗
  6. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Co-author DOI 10.1016/s1470-2045(18)30098-6↗
  7. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Co-author DOI 10.1038/s41416-018-0004-2↗
  8. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pa… Co-author DOI 10.1038/s41416-018-0005-1↗
  9. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-lab… Co-author DOI 10.1016/s0140-6736(16)32409-6↗
  10. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Wi… Co-author DOI 10.1001/jama.2016.4324↗
  11. Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). Co-author DOI 10.1038/bjc.2016.212↗
  12. Any progress in pancreatic cancer? Co-author DOI 10.3109/0284186x.2015.1126350↗
  13. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to… Co-author DOI 10.1016/j.ejca.2014.07.011↗
  14. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. Co-author DOI 10.1093/jnci/djt347↗
  15. Clinical benefit response in pancreatic cancer trials revisited. Co-author DOI 10.1159/000357965↗

Closest collaborators

The 25 strongest of 94 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John P. Neoptolemos · 10 shared papers, 2014–2025 · strength 0.65
  2. Paula Ghaneh · 9 shared papers, 2014–2025 · strength 0.60
  3. Daniel H. Palmer · 8 shared papers, 2014–2025 · strength 0.57
  4. Juan W. Valle · 8 shared papers, 2014–2025 · strength 0.57
  5. Christopher Michael Halloran · 8 shared papers, 2014–2025 · strength 0.57
  6. David Goldstein · 7 shared papers, 2016–2021 · strength 0.42
  7. Alan Anthoney · 7 shared papers, 2014–2021 · strength 0.40
  8. Pascal R. Hammel · 6 shared papers, 2014–2025 · strength 0.40
  9. Thilo Hackert · 4 shared papers, 2017–2025 · strength 0.37
  10. David Cunningham · 4 shared papers, 2017–2025 · strength 0.37
  11. Julia V. Mayerle · 6 shared papers, 2014–2021 · strength 0.36
  12. Markus Wolfgang Büchler · 6 shared papers, 2014–2021 · strength 0.35
  13. Markus M. Lerch · 5 shared papers, 2018–2021 · strength 0.33
  14. Niall Christopher Tebbutt · 5 shared papers, 2014–2021 · strength 0.30
  15. Gary Middleton · 3 shared papers, 2017–2025 · strength 0.27
  16. Olusola Olusesan Faluyi · 3 shared papers, 2017–2025 · strength 0.27
  17. Yuk Ting Ma · 3 shared papers, 2017–2025 · strength 0.27
  18. Paul J. Ross · 3 shared papers, 2017–2025 · strength 0.27
  19. Tim Meyer · 3 shared papers, 2017–2025 · strength 0.27
  20. Harpreet Singh Wasan · 3 shared papers, 2017–2025 · strength 0.27
  21. William Greenhalf · 4 shared papers, 2014–2021 · strength 0.23
  22. Eithne Costello · 4 shared papers, 2014–2021 · strength 0.23
  23. Richard Charnley · 4 shared papers, 2014–2021 · strength 0.23
  24. Christos Dervenis · 5 shared papers, 2014–2019 · strength 0.23
  25. Nils O. Elander · 3 shared papers, 2018–2021 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.